Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Poliovirus | 1 | 2017 | 109 | 0.63 | Why? |
| Poliovirus Vaccine, Oral | 1 | 2017 | 95 | 0.61 | Why? |
| Molecular Diagnostic Techniques | 7 | 2020 | 4239 | 0.40 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3633 | 0.39 | Why? |
| Nucleic Acid Amplification Techniques | 5 | 2020 | 3388 | 0.34 | Why? |
| Mutation | 5 | 2021 | 12376 | 0.29 | Why? |
| Metagenomics | 2 | 2019 | 823 | 0.24 | Why? |
| RNA, Viral | 13 | 2021 | 32276 | 0.22 | Why? |
| Isotachophoresis | 1 | 2020 | 8 | 0.22 | Why? |
| DNA, Fungal | 1 | 2019 | 95 | 0.20 | Why? |
| Transplantation | 1 | 2019 | 72 | 0.19 | Why? |
| DNA Virus Infections | 1 | 2019 | 88 | 0.19 | Why? |
| Microfluidics | 1 | 2020 | 171 | 0.19 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 24 | 0.18 | Why? |
| Lymphoma, T-Cell | 1 | 2018 | 70 | 0.18 | Why? |
| Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.18 | Why? |
| O'nyong-nyong Virus | 1 | 2017 | 9 | 0.18 | Why? |
| Eye Infections, Parasitic | 1 | 2017 | 9 | 0.18 | Why? |
| DNA Viruses | 1 | 2019 | 184 | 0.17 | Why? |
| DNA, Viral | 2 | 2019 | 2521 | 0.17 | Why? |
| Viral Envelope Proteins | 2 | 2020 | 3539 | 0.17 | Why? |
| Severe Dengue | 1 | 2019 | 135 | 0.17 | Why? |
| DNA, Protozoan | 1 | 2017 | 77 | 0.17 | Why? |
| Seizures, Febrile | 1 | 2017 | 59 | 0.17 | Why? |
| Forkhead Transcription Factors | 1 | 2018 | 231 | 0.16 | Why? |
| Clinical Laboratory Techniques | 6 | 2020 | 23402 | 0.16 | Why? |
| Point-of-Care Testing | 2 | 2020 | 2782 | 0.16 | Why? |
| Alphavirus Infections | 1 | 2017 | 68 | 0.16 | Why? |
| Anopheles | 1 | 2017 | 89 | 0.16 | Why? |
| Real-Time Polymerase Chain Reaction | 7 | 2020 | 11367 | 0.16 | Why? |
| Cell-Free Nucleic Acids | 1 | 2019 | 271 | 0.16 | Why? |
| Dengue Virus | 3 | 2019 | 910 | 0.15 | Why? |
| Tumor Virus Infections | 1 | 2017 | 127 | 0.15 | Why? |
| RNA Stability | 1 | 2017 | 285 | 0.15 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 526 | 0.15 | Why? |
| BK Virus | 1 | 2017 | 135 | 0.15 | Why? |
| Reagent Kits, Diagnostic | 3 | 2020 | 2149 | 0.15 | Why? |
| DNA, Bacterial | 1 | 2019 | 835 | 0.15 | Why? |
| Polyomavirus Infections | 1 | 2017 | 156 | 0.15 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2020 | 1439 | 0.15 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 533 | 0.14 | Why? |
| Papillomaviridae | 1 | 2019 | 404 | 0.14 | Why? |
| Nasopharynx | 7 | 2021 | 10224 | 0.14 | Why? |
| Uveitis | 1 | 2017 | 233 | 0.13 | Why? |
| Zika Virus Infection | 2 | 2017 | 1920 | 0.13 | Why? |
| Aspartate Aminotransferases | 1 | 2019 | 1394 | 0.12 | Why? |
| CRISPR-Cas Systems | 1 | 2020 | 1397 | 0.11 | Why? |
| Dengue | 3 | 2019 | 1565 | 0.11 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Nanotechnology | 1 | 2017 | 821 | 0.10 | Why? |
| Uterine Cervical Neoplasms | 1 | 2019 | 842 | 0.10 | Why? |
| Papillomavirus Infections | 1 | 2019 | 861 | 0.10 | Why? |
| Eye Infections, Viral | 1 | 2017 | 517 | 0.10 | Why? |
| Point-of-Care Systems | 2 | 2020 | 2955 | 0.09 | Why? |
| Ebolavirus | 1 | 2015 | 834 | 0.09 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.09 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.09 | Why? |
| Immunologic Tests | 2 | 2021 | 445 | 0.09 | Why? |
| Zika Virus | 2 | 2017 | 1924 | 0.08 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.08 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.08 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.07 | Why? |
| Mass Screening | 4 | 2020 | 8005 | 0.07 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.07 | Why? |
| Specimen Handling | 5 | 2021 | 6190 | 0.07 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.07 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2021 | 13720 | 0.07 | Why? |
| Humans | 37 | 2021 | 930598 | 0.07 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2015 | 1475 | 0.07 | Why? |
| Child, Preschool | 5 | 2021 | 36283 | 0.07 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.07 | Why? |
| False Negative Reactions | 2 | 2020 | 1785 | 0.06 | Why? |
| Antibody Formation | 1 | 2017 | 4038 | 0.06 | Why? |
| California | 2 | 2020 | 2047 | 0.06 | Why? |
| Feces | 1 | 2017 | 4235 | 0.06 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.06 | Why? |
| Sequence Analysis, RNA | 2 | 2021 | 2290 | 0.06 | Why? |
| DNA Fingerprinting | 1 | 2021 | 41 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Reproducibility of Results | 4 | 2020 | 11304 | 0.06 | Why? |
| Viremia | 2 | 2020 | 1020 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.06 | Why? |
| Infant | 3 | 2020 | 30274 | 0.05 | Why? |
| Disease Transmission, Infectious | 2 | 2021 | 9044 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 12 | 0.05 | Why? |
| Viral Nonstructural Proteins | 1 | 2017 | 4810 | 0.05 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2020 | 239 | 0.05 | Why? |
| Stochastic Processes | 1 | 2020 | 369 | 0.05 | Why? |
| Sri Lanka | 1 | 2019 | 241 | 0.05 | Why? |
| Human T-lymphotropic virus 1 | 1 | 2018 | 52 | 0.05 | Why? |
| Zimbabwe | 1 | 2019 | 198 | 0.05 | Why? |
| Conserved Sequence | 1 | 2021 | 751 | 0.05 | Why? |
| Toxoplasmosis, Ocular | 1 | 2017 | 5 | 0.04 | Why? |
| Male | 13 | 2021 | 367725 | 0.04 | Why? |
| Herpes Zoster Ophthalmicus | 1 | 2017 | 17 | 0.04 | Why? |
| Nicaragua | 1 | 2017 | 71 | 0.04 | Why? |
| Africa, Eastern | 1 | 2017 | 90 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Toxoplasma | 1 | 2017 | 61 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Virus Inactivation | 2 | 2017 | 1139 | 0.04 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 243 | 0.04 | Why? |
| Simplexvirus | 1 | 2017 | 124 | 0.04 | Why? |
| Female | 12 | 2021 | 380317 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.04 | Why? |
| Vitreous Body | 1 | 2017 | 161 | 0.04 | Why? |
| Fungi | 1 | 2019 | 471 | 0.04 | Why? |
| Calibration | 1 | 2017 | 307 | 0.04 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.04 | Why? |
| Blood Specimen Collection | 1 | 2019 | 387 | 0.04 | Why? |
| Body Fluids | 1 | 2019 | 451 | 0.04 | Why? |
| Herpesvirus 3, Human | 1 | 2017 | 228 | 0.04 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.03 | Why? |
| Herpes Simplex | 1 | 2017 | 272 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.03 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.03 | Why? |
| Nasal Mucosa | 1 | 2020 | 1218 | 0.03 | Why? |
| Base Sequence | 1 | 2021 | 3581 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.03 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Fever | 2 | 2019 | 7795 | 0.03 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.03 | Why? |
| Genes, Viral | 1 | 2015 | 1428 | 0.02 | Why? |
| Bayes Theorem | 1 | 2019 | 3237 | 0.02 | Why? |
| Child | 4 | 2020 | 70012 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.02 | Why? |
| Genotype | 1 | 2021 | 4697 | 0.02 | Why? |
| Nanoparticles | 1 | 2021 | 2040 | 0.02 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Aged | 6 | 2021 | 215776 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2021 | 3691 | 0.02 | Why? |
| Temperature | 1 | 2017 | 2305 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2019 | 1956 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Viruses | 1 | 2019 | 2238 | 0.02 | Why? |
| Cross Reactions | 1 | 2017 | 4374 | 0.02 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.02 | Why? |
| Computational Biology | 1 | 2019 | 4514 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Vero Cells | 1 | 2015 | 14117 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Animals | 2 | 2017 | 78931 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2015 | 11041 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |